Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy LLY?
Source: NASDAQ.COM
- Acquisition Details: Eli Lilly announced a deal to acquire Ajax Therapeutics and its lead asset AJ1-11095, a once-daily oral JAK2 inhibitor for myelofibrosis, for up to $2.3 billion, including upfront and milestone-based payments.
- Strategic Investment Background: As a founding strategic investor in Ajax, Lilly has long believed in its approach and is excited about AJ1-11095's potential to deliver superior efficacy and tolerability, allowing patients to remain on therapy longer.
- Market Reaction: Eli Lilly's stock traded at $884.65, up 0.05% in pre-market hours on the NYSE, indicating a positive market response to the acquisition, reflecting investor optimism about the new drug's potential.
- Future Outlook: This acquisition not only strengthens Lilly's oncology portfolio but also has the potential to enhance its market share in treating myelofibrosis patients through the clinical success of AJ1-11095, further solidifying its industry leadership.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 987.050
Low
950.00
Averages
1192
High
1500
Current: 987.050
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY SUBMITS SEC FILING FOR EIGHT-PART NOTES OFFERING WORTH UP TO $9 BILLION
- Company Filing: Eli Lilly has filed for an offering of up to $9 billion in senior notes.
- Purpose of Offering: The proceeds from this offering are intended for general corporate purposes.
See More
First Generic Versions of Ozempic Approved in Canada
- Generic Approval: Health Canada approved the first generic versions of Ozempic from Dr. Reddy's Laboratories on April 28, followed by another from Apotex, marking the beginning of increased market competition.
- Market Impact Assessment: Analyst Evan Seigerman noted that these new generics could lead to a decline in international revenue for semaglutide, although the impact on the U.S. market is expected to be limited due to competition from Eli Lilly's Mounjaro.
- Novo's Response Strategy: Emil Kongshøj Larsen, EVP of International Operations at Novo Nordisk, stated that the impact of generics is anticipated to be in the low single digits, highlighting the strong uptake of their savings card strategy in Canada.
- Pricing Policy Change: Canadian policy mandates a 65% price cut to Novo's list price once three generic competitors enter the market, which will significantly influence their future market strategy.
See More
Eli Lilly's Stock Surge and Competitor Analysis
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 weight loss drugs saw sales increase by 125% and 80% in Q1 2026, showcasing robust performance in a rapidly evolving pharmaceutical market, although its P/E ratio stands at 34x, above the industry average of 23x, indicating optimistic market expectations for future growth.
- Novo Nordisk Catching Up: Novo Nordisk's newly launched GLP-1 pill gained traction with 1.3 million prescriptions in the first quarter, suggesting a competitive edge in weight loss effectiveness, prompting the company to raise its full-year 2026 guidance and boosting market confidence.
- Pfizer's Challenges: Pfizer has yet to establish a foothold in the GLP-1 market after having to drop its drug candidate; however, it is actively acquiring promising candidates and advancing oncology and migraine drug development, maintaining its long-standing industry leadership.
- Market Sentiment Analysis: Wall Street's enthusiasm for Eli Lilly has inflated its valuation, prompting caution among long-term investors, while the undervaluation of Novo Nordisk and Pfizer may present greater upside potential, especially in light of overly pessimistic market sentiment.
See More
Eli Lilly's Mounjaro Becomes World's Best-Selling Drug
- Sales Surge: Eli Lilly's Mounjaro achieved $8.66 billion in Q1 2026 sales, a 126% increase from $3.84 billion a year ago, surpassing Merck's Keytruda to become the world's top-selling drug, significantly boosting the company's profits.
- International Market Expansion: Mounjaro generated $4.2 billion in U.S. sales, up 59%, while international sales skyrocketed from $1.2 billion to $4.4 billion, primarily due to its inclusion in China's National Reimbursement Drug List, indicating strong global growth potential.
- New Drug Launch: The U.S. launch of Foundayo, an anti-obesity pill, has attracted over 20,000 patients and received prescriptions from more than 8,000 physicians, expected to further drive revenue growth amid a large global obesity population.
- Optimistic Future Outlook: Eli Lilly anticipates total revenue of $84.4 billion in 2026, nearing $100 billion by 2027, with strong sales from Mounjaro and Zepbound, positioning the company favorably for investors looking for growth opportunities.
See More
Weight-Loss Pills Boost Novo Nordisk and Eli Lilly Shares
- Market Expansion Potential: Novo Nordisk's Wegovy pill achieved first-quarter sales about twice expectations, indicating that oral weight-loss medications could attract millions more patients, potentially driving market growth and alleviating pricing pressures.
- Strong Prescription Data: By mid-April, weekly prescriptions for the Wegovy pill reached approximately 207,000, suggesting that demand from new patients exceeded expectations, with nearly 80% of users being treatment-naive, highlighting significant market expansion potential.
- Changing Competitive Landscape: Since its U.S. launch in April, Eli Lilly's Foundayo has been prescribed by over 8,000 doctors, one-third of whom are new to prescribing oral GLP-1 drugs, indicating that the market is attracting new user demographics.
- Pricing Risks and Market Outlook: Although Novo Nordisk's U.S. sales fell 11% due to lower realized prices, analysts believe the rapid acceptance of oral medications may offset this impact, enabling both companies to grow in the expanding obesity market.
See More
Eli Lilly's Dominance in the Anti-Obesity Drug Market
- Market Leadership: Eli Lilly began to dominate the anti-obesity drug market in 2025 due to stronger products and better execution, despite Novo Nordisk's previous leadership, indicating its significant share in a multi-billion dollar market.
- Significant Profitability: In Q1 2026, Lilly reported a net income of $7.4 billion, more than doubling year-over-year, primarily driven by rapid sales growth of its tirzepatide-based drugs, highlighting that its GLP-1 drug franchise is a key profitability driver.
- Production Capacity Expansion: Lilly has heavily invested in expanding production capacity, providing a structural advantage that smaller competitors cannot replicate, ensuring it can meet the strong demand for GLP-1 drugs in the future.
- Relative Investment Safety: Compared to smaller companies that rely on a single drug, Lilly's diversified pharmaceutical portfolio and strong cash flow demonstrate its relative safety and sustainable growth potential in the anti-obesity drug market.
See More
ELI LILLY SUBMITS SEC FILING FOR EIGHT-PART NOTES OFFERING WORTH UP TO $9 BILLION
- Company Filing: Eli Lilly has filed for an offering of up to $9 billion in senior notes.
- Purpose of Offering: The proceeds from this offering are intended for general corporate purposes.
See More
First Generic Versions of Ozempic Approved in Canada
- Generic Approval: Health Canada approved the first generic versions of Ozempic from Dr. Reddy's Laboratories on April 28, followed by another from Apotex, marking the beginning of increased market competition.
- Market Impact Assessment: Analyst Evan Seigerman noted that these new generics could lead to a decline in international revenue for semaglutide, although the impact on the U.S. market is expected to be limited due to competition from Eli Lilly's Mounjaro.
- Novo's Response Strategy: Emil Kongshøj Larsen, EVP of International Operations at Novo Nordisk, stated that the impact of generics is anticipated to be in the low single digits, highlighting the strong uptake of their savings card strategy in Canada.
- Pricing Policy Change: Canadian policy mandates a 65% price cut to Novo's list price once three generic competitors enter the market, which will significantly influence their future market strategy.
See More
Eli Lilly's Stock Surge and Competitor Analysis
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 weight loss drugs saw sales increase by 125% and 80% in Q1 2026, showcasing robust performance in a rapidly evolving pharmaceutical market, although its P/E ratio stands at 34x, above the industry average of 23x, indicating optimistic market expectations for future growth.
- Novo Nordisk Catching Up: Novo Nordisk's newly launched GLP-1 pill gained traction with 1.3 million prescriptions in the first quarter, suggesting a competitive edge in weight loss effectiveness, prompting the company to raise its full-year 2026 guidance and boosting market confidence.
- Pfizer's Challenges: Pfizer has yet to establish a foothold in the GLP-1 market after having to drop its drug candidate; however, it is actively acquiring promising candidates and advancing oncology and migraine drug development, maintaining its long-standing industry leadership.
- Market Sentiment Analysis: Wall Street's enthusiasm for Eli Lilly has inflated its valuation, prompting caution among long-term investors, while the undervaluation of Novo Nordisk and Pfizer may present greater upside potential, especially in light of overly pessimistic market sentiment.
See More
Eli Lilly's Mounjaro Becomes World's Best-Selling Drug
- Sales Surge: Eli Lilly's Mounjaro achieved $8.66 billion in Q1 2026 sales, a 126% increase from $3.84 billion a year ago, surpassing Merck's Keytruda to become the world's top-selling drug, significantly boosting the company's profits.
- International Market Expansion: Mounjaro generated $4.2 billion in U.S. sales, up 59%, while international sales skyrocketed from $1.2 billion to $4.4 billion, primarily due to its inclusion in China's National Reimbursement Drug List, indicating strong global growth potential.
- New Drug Launch: The U.S. launch of Foundayo, an anti-obesity pill, has attracted over 20,000 patients and received prescriptions from more than 8,000 physicians, expected to further drive revenue growth amid a large global obesity population.
- Optimistic Future Outlook: Eli Lilly anticipates total revenue of $84.4 billion in 2026, nearing $100 billion by 2027, with strong sales from Mounjaro and Zepbound, positioning the company favorably for investors looking for growth opportunities.
See More
Weight-Loss Pills Boost Novo Nordisk and Eli Lilly Shares
- Market Expansion Potential: Novo Nordisk's Wegovy pill achieved first-quarter sales about twice expectations, indicating that oral weight-loss medications could attract millions more patients, potentially driving market growth and alleviating pricing pressures.
- Strong Prescription Data: By mid-April, weekly prescriptions for the Wegovy pill reached approximately 207,000, suggesting that demand from new patients exceeded expectations, with nearly 80% of users being treatment-naive, highlighting significant market expansion potential.
- Changing Competitive Landscape: Since its U.S. launch in April, Eli Lilly's Foundayo has been prescribed by over 8,000 doctors, one-third of whom are new to prescribing oral GLP-1 drugs, indicating that the market is attracting new user demographics.
- Pricing Risks and Market Outlook: Although Novo Nordisk's U.S. sales fell 11% due to lower realized prices, analysts believe the rapid acceptance of oral medications may offset this impact, enabling both companies to grow in the expanding obesity market.
See More
Eli Lilly's Dominance in the Anti-Obesity Drug Market
- Market Leadership: Eli Lilly began to dominate the anti-obesity drug market in 2025 due to stronger products and better execution, despite Novo Nordisk's previous leadership, indicating its significant share in a multi-billion dollar market.
- Significant Profitability: In Q1 2026, Lilly reported a net income of $7.4 billion, more than doubling year-over-year, primarily driven by rapid sales growth of its tirzepatide-based drugs, highlighting that its GLP-1 drug franchise is a key profitability driver.
- Production Capacity Expansion: Lilly has heavily invested in expanding production capacity, providing a structural advantage that smaller competitors cannot replicate, ensuring it can meet the strong demand for GLP-1 drugs in the future.
- Relative Investment Safety: Compared to smaller companies that rely on a single drug, Lilly's diversified pharmaceutical portfolio and strong cash flow demonstrate its relative safety and sustainable growth potential in the anti-obesity drug market.
See More
